These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39316685)

  • 1. Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.
    Ke S; Gálvez JAV; Sun Z; Cao Y; Pollock NR; Chen X; Kelly CP; Liu YY
    J Infect Dis; 2024 Sep; ():. PubMed ID: 39316685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Design of Live Biotherapeutic Products for the Prevention of
    Ke S; Villafuerte Gálvez JA; Sun Z; Cao Y; Pollock NR; Chen X; Kelly CP; Liu YY
    bioRxiv; 2024 May; ():. PubMed ID: 38746249
    [No Abstract]   [Full Text] [Related]  

  • 3. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
    Nagarakanti S; Orenstein R
    Infect Drug Resist; 2023; 16():3137-3143. PubMed ID: 37235073
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of the gut microbiome in colonization resistance and recurrent
    Seekatz AM; Safdar N; Khanna S
    Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbial ecology between
    Kamiya S
    Biosci Microbiota Food Health; 2023; 42(4):229-235. PubMed ID: 37791342
    [No Abstract]   [Full Text] [Related]  

  • 7. Microbiota-Based Live Biotherapeutic Products for
    Monday L; Tillotson G; Chopra T
    Infect Drug Resist; 2024; 17():623-639. PubMed ID: 38375101
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
    Lavoie T; Appaneal HJ; LaPlante KL
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live Biotherapeutic Products for the Prevention of Recurrent
    Pettit NN; Shaeer KM; Chahine EB
    Ann Pharmacother; 2024 Dec; 58(12):1204-1217. PubMed ID: 38546138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection.
    Haifer C; Paramsothy S; Borody TJ; Clancy A; Leong RW; Kaakoush NO
    mSystems; 2021 Feb; 6(1):. PubMed ID: 33531405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota changes associated with
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection.
    Björkqvist O; Rangel I; Serrander L; Magnusson C; Halfvarson J; Norén T; Bergman-Jungeström M
    PLoS One; 2021; 16(4):e0249861. PubMed ID: 33836037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent
    Berry P; Khanna S
    Future Microbiol; 2024; 19(18):1519-1528. PubMed ID: 39320321
    [No Abstract]   [Full Text] [Related]  

  • 15. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
    Orenstein R
    Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers.
    Dsouza M; Menon R; Crossette E; Bhattarai SK; Schneider J; Kim YG; Reddy S; Caballero S; Felix C; Cornacchione L; Hendrickson J; Watson AR; Minot SS; Greenfield N; Schopf L; Szabady R; Patarroyo J; Smith W; Harrison P; Kuijper EJ; Kelly CP; Olle B; Bobilev D; Silber JL; Bucci V; Roberts B; Faith J; Norman JM
    Cell Host Microbe; 2022 Apr; 30(4):583-598.e8. PubMed ID: 35421353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems-ecology designed bacterial consortium protects from severe
    Jenior ML; Leslie JL; Kolling GL; Archbald-Pannone L; Powers DA; Petri WA; Papin JA
    bioRxiv; 2023 Aug; ():. PubMed ID: 37609255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acids impact the microbiota, host, and
    McMillan AS; Theriot CM
    Gut Microbes; 2024; 16(1):2393766. PubMed ID: 39224076
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Wang R
    Front Microbiol; 2023; 14():1182612. PubMed ID: 37228365
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against
    Murphy CK; O'Donnell MM; Hegarty JW; Schulz S; Hill C; Ross RP; Rea MC; Farquhar R; Chesnel L
    World J Gastrointest Pathophysiol; 2023 Aug; 14(4):71-85. PubMed ID: 37727283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.